Silk Road Medical touts TCAR study data

Silk Road Medical today released results from studies of its transcarotid artery revascularization procedure, touting favorable outcomes in treating patients with carotid artery disease. Data from the studies were presented at the Society for Vascular Surgery 2018 Vascular Annual Meeting in Boston. The transcarotid artery revascularization procedure uses the Sunnyvale, Calif.-based company’s Enroute transcarotid stent and neuroprotection system, and is intended to treat blockages in the carotid artery that are at risk of causing a stroke. Results from a two-year study which compared outcomes from 1,182 patients who received treatment with the TCAR procedure to 10,797 patients who received carotid endarterectomy indicated comparable rates of in-hospital stroke or death between the two at 1.6% versus 1.4%, respectively. Data also indicated lower rates of acute cranial nerve injury for TCAR at 0.6% versus a 1.8% rate in CEA patients, shorter operative times at 78 minutes and 111 minutes, respectively, and shorter hospital stays for TCAR patients despite increased age and sickness factors versus the CEA cohort. Results from a separate study comparing TCAR with CEA indicated similar results, with 30-day stroke rates of 1% in TCAR versus 1.1% in CEA. Acute and six-month cranial nerve injury rates were also shown to be smaller in the TCAR cohort than CEA. “Our overall findings showed that while patients receiving TCAR were sicker and more likely to be symptomatic with a ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Vascular Silk Road Medical Inc. Source Type: news